首页|抗炎抗凝双效融合蛋白TAP-SSL5对大鼠长期毒性研究

抗炎抗凝双效融合蛋白TAP-SSL5对大鼠长期毒性研究

扫码查看
目的 研究抗炎抗凝双效融合蛋白TAP-SSL5对大鼠的长期毒性,评价其用药安全性.方法 SD大鼠隔天腹腔注射给药TAP-SSL5 1mg/kg一次,连续给药8周,恢复1周,检测大鼠一般行为状态、体质量变化、血液常规及血液生化、脏器系数等指标.结果 各组大鼠一般行为状态正常、体征正常、体质量无明显异常;血液常规和生化指标未见异常变化;各组动物器官组织病理检查未见明显异常;各组间脏器重量及脏器系数未见明显差异.结论 融合蛋白TAP-SSL5对大鼠长期毒性小,提示其用药安全性较高.
The long-term toxicity study of TAP-SSL5 fusion protein
Objective To investigate the long-term toxicity of anti-inflammatory and anticoagulant tick anticoagulant peptide (TAP)-staphylococcal superantigen like protein-5 (SSL5) fusion protein in normal rats.MethodsSD rats were intraperitoneally injected with TAP-SSL5 (1mg/kg, every other day) for eight weeks and followed up for one week.The general behavior, weight, blood routine test, blood biochemistry and organ indexe were measured.ResultsOur results showed that there were no significantly difference between the TAP-SSL5 treated rats and the control on general behavior, weight, blood routine test, blood biochemistry, organ indexe and pathology.ConclusionThe fusion protein TAP-SSL5 with little long-term toxicity for rats is proved to be a safe drug.

staphylococcal superantigen like protein-5tick anticoagulant peptidefusion proteinlong-term toxicity

房兆飞、胡厚源

展开 >

第三军医大学西南医院心内科,重庆400038

浙江省舟山医院心内科,浙江舟山316000

金黄色葡萄球菌超抗原样蛋白-5 蜱抗凝血肽 融合蛋白 长期毒性

国家高技术研究发展计划(863计划国家重大新药创制课题

2009AA02Z1152013ZX09103003-001

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.(5)
  • 5